CureVac (NYSE: CVAC) — Perfil da empresa, notícias e dados financeiros
CureVac is a biopharmaceutical company developing mRNA-based vaccines and therapies for infectious diseases and cancer.
CureVac
CureVac (NASDAQ:CVAC) is a biopharmaceutical company dedicated to the development and commercialization of innovative treatments and therapies. Specializing in messenger RNA (mRNA) technology, CureVac focuses on creating vaccines and therapeutic solutions for infectious diseases, as well as treatments for cancer and rare diseases. The company is actively involved in research and development projects, aiming to leverage its proprietary mRNA platform to address unmet medical needs and improve patients' lives worldwide. CureVac's objectives include advancing its pipeline of mRNA-based products through clinical trials, securing regulatory approvals, and establishing partnerships to enhance its technological capabilities and expand its global reach.
Resumo
Operações
Produtos e/ou serviços de CureVac
- CVnCoV, an investigational mRNA-based COVID-19 vaccine designed for protection against the SARS-CoV-2 virus.
- mRNA technology platform for developing vaccines and therapeutics across infectious diseases, oncology, and rare diseases.
- Rabies vaccine project, utilizing proprietary mRNA technology to offer a more rapid and reliable production of vaccines.
- CV7202, a prophylactic vaccine against the Yellow Fever virus, showcasing the versatility of its mRNA platform.
- Collaboration with GSK to develop next-generation mRNA vaccines for COVID-19, aiming for improved protection and broader efficacy.
- Partnership for the development of mRNA-based cancer therapies, focusing on utilizing the body's own immune system to fight cancer.
equipe executiva do CureVac
- Dr. Alexander Zehnder M.B.A., M.D.CEO, MD & Member of Management Board
- Mr. Axel-Sven MalkomesCFO & Member of Executive Board
- Dr. Malte Greune Ph.D.COO, Member of Management Board & MD
- Dr. Myriam Mendila M.D.Chief Scientific Officer, Head of R&D, MD & Member of the Management Board
- Mr. Thaminda RamanayakeChief Business Officer & Member of Executive Board
- Dr. Sarah FakihVice President of Corporate Communications & Investor Relations
- Mr. Marco Rau L.L.M., Ph.D.General Counsel
- Slavica Stevanovic-HeckHead of Human Resources
- Dr. Ulrike Gnad-Vogt M.D., Ph.D.Senior VP & Area Head of Oncology
- Dr. Patrick BaumhofSenior Vice President of Technology
Principais indicadores financeiros
Resultados divulgados pela CureVac , em EUR.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 535,2 mi | 177,7 mi | 162,2 mi | |
| 53,8 mi | -274,2 mi | -260,2 mi | |
| 67,4 mi | -249,5 mi | -249 mi | |
| 103 mi | -412,3 mi | -411,7 mi |